• Senti Biosciences entered securities purchase agreement on April 27, 2026 for private placement of up to USD 40 million of Senior Secured Convertible Notes issued by subsidiary Senti Holdings.
• Initial tranche set at USD 10 million, subject to closing conditions that include completion of holding company reorganization completed on April 24, 2026.
• Second tranche may add up to USD 30 million, subject to Celadon election and execution of definitive documents within 30 days for potential CVR transaction tied to SENTI-202 milestones.
• Notes mature six months after initial closing date, with cash repayment set at 200% of outstanding principal if not converted or exchanged.
• Celadon affiliate agreed to pay USD 9.7 million for initial notes, with potential post-exchange ownership rising to 54.6% following stockholder approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-029320), on May 01, 2026, and is solely responsible for the information contained therein.